Pregabalin chemical structure
| (S)-3-(aminomethyl)-5-methylhexanoic acid|
| CAS number |
| ATC code |
| PubChem |
| DrugBank |
|Molecular weight||159.23 g.mol-1|
|Elimination half-life||5–6.5 hours|
|Pregnancy category||B3 (Au), C (U.S.)|
|Legal status||S4 (Au), POM (UK), Schedule V (U.S.)|
|Routes of administration||Oral|
Pregabalin (INN) (IPA: [prɪˈgæbələn]) is an anticonvulsant drug used for neuropathic pain, as an adjunct therapy for partial seizures, and in generalized anxiety disorder. It was designed as a more potent successor to gabapentin. Pregabalin is marketed by Pfizer under the trade name Lyrica.
Pregabalin was initially developed by biochemist Richard Silverman at Northwestern University in the United States. The drug was approved in the European Union in 2004. Pregabalin received U.S. Food and Drug Administration (FDA) approval for use in treating epilepsy, diabetic neuropathy pain and post-herpetic neuralgia pain in June 2005, and appeared on the U.S. market in fall 2005.
Pregabalin is indicated for:
- Treatment of neuropathic pain in adults
- Adjunctive therapy in adults with partial seizures with or without secondary generalization
- Fibromyalgia pain. The FDA has approved Pregabalin as an indicated use on June 21, 2007.
- Very common (>10% of patients): dizziness, drowsiness
- Common (1–10% of patients): visual disturbance (including blurred vision, diplopia), ataxia, dysarthria, tremor, lethargy, memory impairment, euphoria, weight gain, constipation, dry mouth, peripheral edema, loss or decrease of libido, erectile dysfunction
- Infrequent (0.1–1% of patients): depression, confusion, agitation, hallucinations, myoclonus, hypoaesthesia, hyperaesthesia, tachycardia, excessive salivation, sweating, flushing, rash, muscle cramp, myalgia, arthralgia, urinary incontinence, dysuria, thrombocytopenia, Kidney calculus
- Rare (<0.1% of patients): neutropenia, first degree heart block, hypotension, hypertension, pancreatitis, dysphagia, oliguria, rhabdomyolysis
No pharmacokinetic interactions have been demonstrated in vivo. The manufacturer notes some potential pharmacological interactions with oxycodone, lorazepam and ethanol (alcohol). Concurrent use may increase the central nervous system effects of these medications (e.g. drowsiness, effects on concentration).
- ↑ http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-25-2002/0001827864&EDATE=
- ↑ http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-28-2006/0004480854&EDATE=
- ↑ Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist 2005;70(144):43633-5. PMID 16050051
- ↑ FDA Approves First Drug for Treating Fibromyalgia. URL accessed on 2007-07-04.
- ↑ Pfizer's Lyrica Approved for the Treatment of Generalized Anxiety Disorder (GAD) in Europe. Press release. Retrieved on 2007-07-04.
- ↑ 6.0 6.1 Pfizer Australia Pty Ltd. Lyrica (Australian Approved Product Information). West Ryde: Pfizer; 2006.
- ↑ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3
- Lyrica (pregabalin) drug label/data at Daily Med from U.S. National Library of Medicine, National Institutes of Health.
- Pfizer website for Lyrica
- U.S. prescribing information
- FDA press release approving Lyrica for fibromyalgia treatment